Connect with us

BIOTECH

Insys Therapeutics Inc (NASDAQ:INSY) Reports Availability of SYNDROS

Published

on

Insys Therapeutics Inc

Insys Therapeutics Inc (NASDAQ:INSY) reported that SYNDROS™ has been made available for health care executives to prescribe. It is stocked with most of the key wholesalers for retail pharmacy ordering or via the company’s Specialty Pharmacy Network.

The details

SYNDROS can be defined as a liquid formulation of the pharma Hemp dronabinol. It is indicated for application in treating anorexia linked with weight loss in people with Acquired Immune Deficiency Syndrome and vomiting and nausea linked with chemotherapy in people with cancer who have failed to respond sufficiently to conventional antiemetic therapies. Saeed Motahari, the CEO and President of Insys, reported that the release of SYNDROS showcases a major milestone for them.

SYNDROS is the second offering entirely advanced and commercialized by Insys Therapeutics. They are thrilled to make SYNDROS accessible to those patients in need and expect to bringing additional unique therapeutic solutions to more patients in the imminent future.

Stephen Sherman, the SVP of Regulatory Affairs with Insys, reported that SYNDROS is the FDA-permitted liquid dronabinol. It showcases a viable option for the delivery of dronabinol and will meet a considerable unmet need for cancer patients undertaking chemotherapy who fail conventional antiemetics and AIDS patients who witness weight loss.

There are currently more than 15 million people diagnosed with cancer in the U.S.  Affecting around 80% of people undergoing chemotherapy, CINV is one of chemotherapy’s most devastating side effects and often attributed as a major reason behind premature discontinuation of cancer treatment. Irrespective of the availability of numerous antiemetics, CINV continues to be a major concern for the cancer patient.

SYNDROS™ may cause cognitive and psychiatric effects and impair physical and/or mental abilities. People with cardiac disorders may witness syncope, tachycardia, hypotension or hypertension. Products should be discontinued containing metronidazole or disulfiram at least 14 days before and should not be administer one week after treatment with SYNDROS™.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Title

Uncategorized3 days ago

Top 15 Essential Oils + Health Benefits

Top 15 Essential Oils + Health Benefits Each and every essential oil contains compounds with unique healing and therapeutic benefits....

Uncategorized3 days ago

Using Hemp Oil in Cooking

Hemp oil has many advocates. The oil from hemp seeds is rich in omega-3 and omega-6 essential fatty acids. This makes...

Uncategorized1 week ago

Best Oil Producers of 2018

Millionaires are being made by the moment in the medical marijuana industry. Venture capital firms, private equity firms, and even...

MyDx Inc MyDx Inc
Health3 weeks ago

MyDx Inc. (OTCMKTS:MYDX) Initiates Clinical Trial of Cannabis Formula for The Treatment of Chronic Low Back Pain

San Diego, CA based MyDx Inc. (OTCMKTS:MYDX) has announced the controlled trial of the cannabis formula for the treatment of...

Business3 weeks ago

Fastfunds Financial Corporation (OTCMKTS:FFFC) Is All Set to Launch Affinity Connextions Program Targeting MMJ Industry

Fastfunds Financial Corporation (OTCMKTS:FFFC) has announced the completion of all necessary formalities to introduce an Affinity Connextions Program through a...

Innovative Industrial Properties Inc Innovative Industrial Properties Inc
Business3 weeks ago

Innovative Industrial Properties, Inc (NYSE:IIPR) Unveils Exercise Of Underwriter’s Option To Purchase Common Stock Shares

Innovative Industrial Properties, Inc (NYSE:IIPR) announced recently that it has obtained the exercise of the underwriter’s option to buy additional...

Business3 weeks ago

Next Generation Management Corporation (OTCMKTS:NGMC) Updates On New Medical Marijuana System in Oregon

Nextgen Holdings, a subsidiary of the Next Generation Management Corporation (OTCMKTS:NGMC) recently updated its stockholders with the ongoing Medical Marijuana...

INDUSTRIAL HEMP3 weeks ago

Weed Inc’s (OTCMKTS:BUDZ) Performance Is Getting Higher

Weed Inc (OTCMKTS:BUDZ) has for a long time been enjoying the momentous highs for the past few months. The company’s...

INDUSTRIAL HEMP3 weeks ago

Namaste Technologies Inc (OTCMKTS:NXTTF) Signs A Share Purchase Agreement With Cannbit Ltd

Namaste Technologies Inc (OTCMKTS:NXTTF) announced recently that it signed a non-binding Letter of Intent (LOI) with Cannabit Limited where the...

INDUSTRIAL HEMP3 weeks ago

MariMed Inc. (OTCMKTS:MRMD) Plans To Expand Its Cannabis Business

MeriMed Inc. (OTCMKTS:MRMD) announced its grand plans to expand business into the emerging cannabis industry. Furthermore, the company intends to...

Advertisement
Advertisement
Advertisement